Investors / United States / Third Rock Ventures
Third Rock Ventures
Venture capital · Boston, MA, United States · North America
Third Rock Ventures is a biotechnology venture capital firm that founds and builds new companies around scientific discoveries. It takes an active operational role in its portfolio companies, including serving in interim leadership roles and on boards.
Invests inHealthcare & BiotechAI & Machine LearningFintech
In its own wordsbiotechnologytherapeuticsdrug discoverylife sciencescompany creationhealthcare
Your fit with Third Rock Ventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsThird Rock Ventures lists 34 checked portfolio companies on its own site and is named in 7 funding rounds, 2 of them as lead. Its most frequent entry is Growth, 43% of the companies with a known first round. Its largest themes are Healthcare & Biotech (46%), AI & Machine Learning (17%) and Fintech (15%). 89% of its companies are based in United States. It invests most often alongside Casdin Capital, General Catalyst and ARCH Venture Partners.
Counts come from funding rounds that name Third Rock Ventures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Third Rock Ventures' whole history. Rounds on record name 7 companies; its own site lists 34. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 29% |
| Series B | 29% |
| Growth | 43% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 1 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 1 | 0 |
| '25 | 3 | 1 |
| '26 | 2 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 72th | 34 companies |
| Recent activity | 76th | 3 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 74th | 9% of companies confirmed by a round |
| Sector focus | 80th | 46% in its largest sector |
| Reach | 70th | 4 countries |
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 46% | 15% |
| AI & Machine Learning | 17% | 18% |
| Fintech | 15% | 12% |
| Industrial & Manufacturing | 7% | 7% |
| Consumer | 4% | 3% |
| E-commerce & Marketplaces | 2% | 6% |
| Cybersecurity | 2% | 4% |
| Real Estate & Construction | 2% | 3% |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Casdin Capital | 7 |
| General Catalyst | 4 |
| ARCH Venture Partners | 3 |
| Andreessen Horowitz | 3 |
| Foresite Capital | 3 |
| GV | 3 |
| RA Capital | 3 |
| Astir Ventures | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers34100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Co-investor network
who it backs companies with, and who they back togetherCompare Third Rock Ventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Third Rock Ventures| Date | Company | Stage |
|---|---|---|
| 30 Jun 2026 | Series C+ Led | |
| 15 Apr 2026 | Series C+ | |
| 18 Dec 2025 | Series A | |
| 4 Nov 2025 | Series A Led | |
| 29 Jul 2025 | Series B | |
| 3 Dec 2024 | Series C+ | |
| 26 May 2020 | Series B |
Round details for Third Rock Ventures
Amounts, full round histories and every co-investor in Third Rock Ventures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
34 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Ablexis delivers a superior, next generation transgenic mouse platform for the discovery of therapeutic antibodies. | Healthcare & Biotech | Portfolio page | ||
| Afferent develops and provides machine health intelligence products and services for various industries | Industrial & ManufacturingAI & Machine Learning | Portfolio page | ||
| Agios develops therapies for people with rare diseases, with a focus on hemolytic and acquired anemias. | Healthcare & Biotech | Portfolio page | ||
| Alcresta Therapeutics develops rare disease, enzyme-based products helping to address fat malabsorption in patients who are enterally fed at home or in the hospital. | Healthcare & Biotech | Portfolio page | ||
| Ambys is a mood-first social app where users can post their feelings and connect with others without judgment. | Media & EntertainmentHealthcare & Biotech | Portfolio page | ||
| ARTBIO develops alpha radioligand therapies for cancer treatment. | Healthcare & Biotech | Jul 2025Series B | Page + round | |
| Azalea Therapeutics is enabling precision genome engineering directly inside the body, with an initial focus on creating cancer immunotherapies in vivo. | Healthcare & Biotech | Nov 2025Series A | Funding round | |
| Rhythm builds the Light Machine, an instrument that brings the full strength of the sun indoors | Healthcare & BiotechConsumer | Portfolio page | ||
| Blueprint turns ideas into wiring diagrams, parts lists, and purchase information | AI & Machine LearningIndustrial & Manufacturing | Portfolio page | ||
| Corvia Medical, Inc. develops a system for improving quality of life and reducing heart failure related symptoms and events in patients with heart failure. | Healthcare & Biotech | Portfolio page | ||
| CytomX is a clinical-stage biopharmaceutical company researching and developing therapies to treat cancer. | Healthcare & Biotech | Portfolio page | ||
| Decibel develops a platform for introducing new traits to crops after seed production, allowing for real-time trait delivery and adaptation to changing conditions. | AI & Machine LearningAI & Machine Learning | Portfolio page | ||
| Editas Medicine develops transformative and durable medicines for people living with serious diseases using CRISPR gene editing technology | Healthcare & Biotech | Portfolio page | ||
| Element Science develops and commercializes a wearable cardioverter defibrillator called Jewel | Healthcare & Biotech | Portfolio page | ||
| Ember develops an AI revenue cycle platform for healthcare providers to automate and manage their revenue integrity and claims processing | Healthcare & BiotechAI & Machine Learning | Portfolio page | ||
| Flare Therapeutics designs small molecules to treat disease, particularly cancer, by regaining transcriptional control hijacked by cancer cells. | Healthcare & Biotech | Jun 2026Series C+ | Funding round | |
| The company develops and sells a hardware device called Passport for securing digital assets | CybersecurityFintech | Portfolio page | ||
| Pliant provides a business credit card solution and payment platform for companies to manage their finances and automate payment processes. | FintechE-commerce & Marketplaces | Portfolio page | ||
| Goldfinch Finance provides access to private credit funds on a blockchain platform. | FintechFintech | Portfolio page | ||
| Insitro develops medicines using artificial intelligence and data from cellular experiments and population-scale genetics. | Healthcare & Biotech | May 2020Series B | Page + round |
About this data
site last read 5 Nov 2026- Site
- thirdrockventures.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 26 May 2020
- Companies checked
- 34
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Third Rock Ventures' profile as data
Pull Third Rock Ventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/thirdrockventures.com
# also
GET /v1/firms/thirdrockventures.com/portfolio
GET /v1/firms/thirdrockventures.com/coinvestors
GET /v1/firms/thirdrockventures.com/news